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Background: A large number of people in both developing and developed countries rely on medicinal plant
products to maintain their health or treat illnesses. Available evidence suggests that medicinal plant consumption
will remain stable or increase in the short to medium term. Knowledge on what factors determine medicinal plant
consumption is, however, scattered across many disciplines, impeding, for example, systematic consideration of
plant-based traditional medicine in national health care systems. The aim of the paper is to develop a conceptual
framework for understanding medicinal plant consumption dynamics. Consumption is employed in the economic
sense: use of medicinal plants by consumers or in the production of other goods.
Methods: PubMed and Web of Knowledge (formerly Web of Science) were searched using a set of medicinal plant
key terms (folk/peasant/rural/traditional/ethno/indigenous/CAM/herbal/botanical/phytotherapy); each search terms
was combined with terms related to medicinal plant consumption dynamics (medicinal plants/health care/
preference/trade/treatment seeking behavior/domestication/sustainability/conservation/urban/migration/climate
change/policy/production systems). To eliminate studies not directly focused on medicinal plant consumption,
searches were limited by a number of terms (chemistry/clinical/in vitro/antibacterial/dose/molecular/trial/efficacy/
antimicrobial/alkaloid/bioactive/inhibit/antibody/purification/antioxidant/DNA/rat/aqueous). A total of 1940
references were identified; manual screening for relevance reduced this to 645 relevant documents. As the
conceptual framework emerged inductively, additional targeted literature searches were undertaken on specific
factors and link, bringing the final number of references to 737.
Results: The paper first defines the four main groups of medicinal plant users (1. Hunter-gatherers, 2. Farmers and
pastoralists, 3. Urban and peri-urban people, 4. Entrepreneurs) and the three main types of benefits (consumer,
producer, society-wide) derived from medicinal plants usage. Then a single unified conceptual framework for
understanding the factors influencing medicinal plant consumption in the economic sense is proposed; the
framework distinguishes four spatial levels of analysis (international, national, local, household) and identifies and
describes 15 factors and their relationships.
Conclusions: The framework provides a basis for increasing our conceptual understanding of medicinal plant
consumption dynamics, allows a positioning of existing studies, and can serve to guide future research in the area.
This would inform the formation of future health and natural resource management policies.
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Medicinal plants, defined as plants used for maintain-
ing health and/or treating specific ailments, are used
in a plethora of ways in both allopathic and traditional
systems of medicine in countries across the world. Even
people using only allopathic medicine throughout their
lives are likely to be somewhat medicinal plant reliant as
20-25% of drugs prescribed are plant derived [1]. There
is thus a medicinal plant reliance continuum: from
people who consume solely allopathic medicine to users
having no alternative to using medicinal plants for a
majority of their health care treatments. It is unfortu-
nately not possible to even roughly estimate the absolute
number of people, or the frequency of medicinal plant
use, at different locations along the medicinal plant reli-
ance continuum. Official statistics on medicinal plant
trade and consumption are scant and not very inform-
ative as medicinal plant products are often part of the
informal economy (the part of the economy not moni-
tored by the government, taxed or included in national
statistical estimates such as the gross national product)
and thus not recorded, or recording aggregates medi-
cinal plants with other items. Throughout this paper we
use the term “consumption” in the economic sense: use
of medicinal plants by consumers or in the production
of other goods. The term is not used in any medical
sense, e.g. to denote oral administration of a drug.
The World Health Organization has estimated that
80% of the world’s population relies solely or largely on
traditional remedies for health care [2] and there is
speculation that more than two billion people may be
heavily reliant on medicinal plants [3]. Although consid-
erable uncertainty surrounds these often cited figures,
there is no doubt that medicinal plants play an import-
ant role in the livelihoods and welfare of a vast number
of people in both developed and developing countries.
The importance of medicinal plants in health care is in-
creasingly recognized in the health sector as exemplified
by discussions of the role of traditional medicine in con-
tributing to achieving the Millennium Development
Goals (MDG), three of which are directly health related
[4], and by work towards European harmonized criteria
for the assessment of herbal medicinal products [5,6].
When evaluating or developing nominal and functional
health policies, it is crucial to understand the current
role of medicinal plants and, in order to be able to assess
the impacts of policy changes, to understand who is
dependent how on medicinal plants. Will consumption
increase in some locations and decrease in others?
Should care be taken to reach certain groups of people?
Health policies are only rarely integrated or coordinated
with other sector policies (such as agricultural or
environmental policies) with the result that health
investments are narrowly confined to the health sector(e.g. [7]). Increased attention to medicinal plant con-
sumption and its dynamics may contribute to the devel-
opment of collaboration across the natural resources
and health sectors, resulting in more comprehensive and
efficient health policies.
Perhaps as a consequence of the ubiquitous worldwide
use of medicinal plants, information on medicinal plant
consumption is scattered across a wide range of disci-
plines and sectors, and there is no structured overview
of state-of-knowledge. We argue that this impedes the
systematic consideration of plant-based traditional medi-
cine in national health care systems in many countries,
although some notable examples of integration of herbal
medicine into national health legislations exist (e.g. the
European Directive on Traditional Herbal Medicinal
Products). The objective of this paper is to improve our
knowledge of medicinal plant consumption. We argue
that there are many reliance dimensions linking humans
and medicinal plants, and we use this as the starting point
to identify the main groups of medicinal plant users and
the main types of benefits they derive from medicinal
plant usage. We then proceed to identify the factors
determining medicinal plant consumption patterns and
structure these in a conceptual framework. In other
words, we address the two questions: (i) in what ways and
to whom are medicinal plants important, and (ii) what
factors determine medicinal plant consumption?
Methods
The global peer-reviewed literature on medicinal plant
use patterns and factors influencing these provided the
foundation for outlining main users and benefit types.
The large amount of relevant literature is found across
many disciplines, for example ethnobotany, geography,
anthropology and medicine, and the initial search was
thus broad using search terms that would be most likely
to generate studies that included medicinal plant con-
sumption related aspects. We initially focused on the
term traditionala medicine and traced its history. This
term was initially known as “primitive” medicine studied
by anthropologists in third world countries. After World
War II the term was succeeded by “peasant” and “folk”
medicine, then “rural” medicine [8], and now the term
in vogue is “traditional” (e.g. [9,10]). Traditional medicine
is increasingly consumed in western countries, where it
is commonly called “alternative/complementary/holistic/
herbal/indigenous/integrative/native/natural/non-toxic/
oriental/unconventional” and “fringe/non-traditional/
unproven/unscientific”. It excludes what has been termed
“allopathic/conventional/mainstream/modern/orthodox/
western”. In our literature search we focused on
the main terms used historically (folk/peasant/rural/
traditional), terms that are of recent importance (ethno/
indigenous/CAM) with the addition of terms that
Smith-Hall et al. Journal of Ethnobiology and Ethnomedicine 2012, 8:43 Page 3 of 11
http://www.ethnobiomed.com/content/8/1/43are entirely medicinal plant based (herbal/botanical/
phytotherapy). We searched PubMed and the Thomson
Reuters Web of Knowledge, with no language restric-
tions, and combined each of the search terms with other
terms (medicinal plants/health care/preference/trade/
treatment seeking behavior/domestication/sustainability/
conservation/urban/migration/climate change/policy/
production systems) to focus on studies including
aspects of medicinal plant use and consumption. To
eliminate studies that are not directly focused on medi-
cinal plant use, such as chemical studies on plant consti-
tuents or clinical studies, the search was limited by a
number of terms (chemistry/clinical/in vitro/antibacterial/
dose/molecular/trial/efficacy/antimicrobial/alkaloid/bioactive/
inhibit/antibody/purification/antioxidant/DNA/rat/aqueous).
The search was last updated in August 2012. Taking into
account 203 overlapping references in the two databases,
a total of 1940 references were identified. A manual
screening of the abstracts further eliminated 1295 refer-
ences that were ethnobotanical descriptions (446) (only
studies containing information directly relevant to the
conceptual framework was included, e.g. a study docu-
menting that a particular product from a particular spe-
cies is used to treat a particular ailment in a particular
location does not add to or deduct from the framework),
concerned with safety and efficacy (239), veterinary
medicine (39) or in other ways not relevant to the topic
(574). The key term search thus yielded a total of 645
relevant documents. This formed the basis of the con-
ceptual framework; as this emerged inductively add-
itional targeted literature searches were undertaken to
further clarify factors and links at especially the inter-
national and national levels. This identified an additional
92 documents. To avoid excessive referencing, the refer-
ences included in the text are generally peer-reviewed
reviews, comparative studies, and illustrative case studies.
The full list of references, including how each reference
is linked to the conceptual framework, is available in the
Additional file 1: Appendix.
Results
How and to whom are medicinal plants important?
We distinguish three main types of benefits accruing
from medicinal plant use: consumer, producer and
society-wide benefits. Based on an existing typology [11],
we classify users in four main groups: 1. Hunter-gath-
erers, 2. Farmers and pastoralists, 3. Urban and peri-
urban (residing in areas between suburbs and rural
areas) people, and 4. Entrepreneurs.
Types of benefits
Consumer benefits are (typically non-monetary) indirect
benefits accruing from consumption of medicinal plant
products, either raw or in processed form (e.g. [12,13]).Benefits are derived through both maintenance of health
and treatment of illnesses. Quantification of these bene-
fits is difficult but they may constitute the most import-
ant type of benefit in value terms. For example, it has
been estimated that more than 50% of people facing ill-
ness in a rural setting in Burkina Faso consumed trad-
itional medicine [14]. However, huge variation in the
importance of consumer benefits across user groups and
countries is to be expected.
Producer benefits are understood as (typically monet-
ary) direct benefits from production of and trade in me-
dicinal plants, plant based medicines, and plant based
medicine services such as those provided by traditional
medicine therapists (e.g. [15,16]). Benefits include har-
vester income from sale of medicinal plants and income
to economic agents along the marketing chain where
value-addition takes place, e.g. through transport and
processing. Individual income levels range from mar-
ginal to substantial.
Society-wide benefits include employment opportun-
ities in the medicinal plant based trade and industry,
from processing to retailers and health care providers, as
well as government revenues from medicinal plant
related taxes (e.g. harvesting licenses, transport permits,
custom duties and value-added tax). Trade may be of
national economic importance [17]. In countries where
conventional health care systems fail to reach or under-
serve many people (e.g. [18]), traditional plant based
medicines, by making health care (more) available and
affordable, may result in a more healthy labour force
with economy-wide productivity gains; this could be a
major, not yet quantified, benefit.
Main user groups and associated medicinal plant benefits
The huge differences in medicinal plant reliance between
user groups [19] are visualized in the medicinal plant
reliance continuum (Figure 1). The number of people at
either end of the continuum is likely to be small: (i) at
one extreme, few people use no medicine at all or only
allopathic medicine not derived from plants, and (ii) at
the other extreme, people entirely dependent on trad-
itional medicine, such as in isolated hunter-gatherer
communities, may have access to treatments based on
minerals, animals and rituals (e.g. [20]).
Hunter-gatherers have strong cultural attachment to
the environment and usually remain relatively isolated,
having limited contact with market economies. They
primarily rely on hunting and gathering or shifting culti-
vation and they are among the poorest of the poor
(e.g. [21]). The relative number of people in this group is
limited. Consumer benefits are generally very important
for this user group. Hunter-gatherer communities are
often remote and hence have the least access to public
health care (e.g. [22,23]). This, combined with the cultural
No reliance Full reliance 
Consumers using only 
allopathic medicine 
Employees in medicinal 
plant industries 
Rural and urban people 
choosing between allopathic 
and traditional systems 
Small-scale farmers with low 
physical and/or economic 
access to allopathic medicine 
Isolated hunter-gatherer 
communities 
Figure 1 The medicinal plant reliance continuum and examples of reliance.
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usually leads to a relatively high reliance on medicinal
plants for subsistence use.
Farmers and pastoralists typically occupy the land-
scape between forests and towns/cities and are engaged
in subsistence and/or commercial agriculture, including
animal husbandry. There is huge variation in this group
ranging from landless farmhands to smallholders to
large industrial and green revolution farmers [24]; the
relative number of people in the group is high. Producer
benefits to most small and medium scale farmers and
pastoralists in developing countries from the production
or collection of medicinal plants are limited due to a
lack of access to technologies and exploitative market
structures [25,26]. The degree of consumer benefits will
typically vary with physical and economic access to the
public health infrastructure [11,27-29], e.g. large farmers
will have better economic access than landless (but see
[30] for documentation of a positive correlation between
wealth and the use of traditional medicine).
Urban and peri-urban people in developing and devel-
oped countries exhibit different medicinal plant con-
sumption patterns. In developing countries, where the
proportion of people living in urban areas is rising [31],
the group includes a large number of poor that have
migrated from rural areas to become part of the infor-
mal urban or peri-urban sector, and a smaller middle
class with jobs in the formal sector (e.g. [32]) – though
there are important exceptions, e.g. the large and rapidly
expanding middle class in China. Medicinal plant con-
sumption varies with factors such as income and access
to public health facilities [27,33], ethnicity and gender
[34] and ethnobotanical knowledge [35]. In developed
countries, the main distinction is between the relatively
poor and the well-off, where higher income [36] but also
lack of access to modern treatment [37] predicts use
of traditional medicine. The use of traditional medicine
to prevent illness is apparently common [38] and persist-
ent [36]. Generally, a high frequency of traditional medi-
cine use is reported among migrants in developed
countries [39,40].
Entrepreneurs are individuals who seek to capitalize on
potentially profitable endeavours often associated withsome degree of risk taking. They include actors along
the medicinal plant marketing chain (traders, wholesa-
lers, retailers), processors varying from small rural-based
distillation units to huge urban based factories serving
international markets, and health service providers such
as traditional healers and general practitioners (e.g.
[16,22,41-43]). The relative number in this group is lim-
ited but their functions are essential to make medicinal
plants available to consumers. While producer benefits
are intrinsically linked to entrepreneurs, consumer bene-
fits depend on entrepreneurs’ access to public health fa-
cilities and levels of income.
Determinants of medicinal plant consumption: A
conceptual framework
Analyzing medicinal plant consumption is very complex:
there is a huge number of medicinal plant species from a
large variety of habitats under different forms of manage-
ment. They are used by different types of users in a vast
number of preventive and curative treatments and offered
by discrete types of therapists. To enable a systematic ap-
proach to understanding medicinal plant consumption, we
here present a conceptual framework (Figure 2) focusing
on the factors influencing the supply and demand of medi-
cinal plants. There are four spatial levels of analysis: inter-
national, national, local, and household. At each level, three
to four main factors and links (indicated by arrows) be-
tween factors are identified; each link is assigned a unique
number (used when describing the links below). Note that
arrows do not indicate simple uni-directional causalities, e.
g. climate change may result in change in species compos-
ition in a forest which may simultaneously diminish the
supply of one medicinal plant species while increasing the
supply of another (link I1); impact is site and species spe-
cific. Also note that there are different types of impacts.
Direct impacts are caused by physical or biological
factors that influence medicinal plant consumption without
interacting with social systems or other mechanisms, e.g.
the direct impact of climatic changes on medicinal plant
supplies through changed growth conditions. Indirect
impacts are effects from economic, socio-political, institu-
tional, demographic, technological and cultural activities

















































* Relative to pre-existing situation
Each link is numbered (e.g. first link at International levl is I1) and referred to in the text
Figure 2 Conceptual framework for analyzing changes in medicinal plant consumption.
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areas supplying medicinal plants (N1). Indirect impacts are
site specific. Derived impacts are economy-wide and not
restricted to particular sites, e.g. the impact of increased
budgets for pluralistic national health care systems on
health care options (N3). Finally, it should be noted that
predicted changes in variables at national level and below
are relative, i.e. influenced by the pre-existing situation. For
instance, changes in medicinal plant supply are influenced
by pre-existing factors such as the reproductive morph-
ology of a species (I1).
In the following, each analytical level is explained,
including a description of each causal factor and the lin-
kages between factors. We highlight important assump-
tions and gaps in knowledge.
International level
There is now near unanimous agreement that anthropo-
genic greenhouse gas emissions will change the Earth’s cli-
mate [44]. Climate change will directly affect medicinal
plant supply through changes in habitat structure and/or
plant species composition (I1) [45] and may also changeterms-of-trade (I3) as the relative cost of producing differ-
ent items changes between countries. For instance, it has
been predicted that climate changes will lead to de-
creasing average crop yields in developing countries
and increased yields in developed countries [46].
Terms-of-trade are influenced by a large number of
factors, including international flows of labour and
capital and international commodity prices, which may
all impact on the structure of national production
systems (I5) (e.g. [47]). Climate change is also expected
to affect human health (I2), mainly adversely,
e.g. through an increase in vector-borne infectious
diseases and extreme weather events (e.g. [48,49]).
Finally, global policies and international multilateral
conventions, such as the Convention on Biological
Diversity and the Agreement on Trade-Related
Aspects of Intellectual Property Rights, influence
national policies, legislation, and budgets (I4) with
impacts on both medicinal plant supply and demand.
For example, international research on potential herbal
medicines may be discouraged by national protection-
ist policies formulated to prevent biopiracy [50,51].
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Policies and budgets influence the supply of medicinal
plants through decisions affecting resource management
(N1). For example, enhancement of productivity can take
place through resource management aiming at increasing
the production area, protecting degraded production
areas, and introducing more efficient technologies. Con-
versely, decreases in productivity result from elimination
or degradation of production units, e.g. through policies
promoting the expansion of agriculture in forests
(e.g. [52,53]). Indirect impacts also arise from national
allocations to infrastructure development and mainten-
ance, including for roads that may indirectly impact the
resource base through deforestation [54-56]. In many
developing countries forest areas are presently shrinking
and the forest quality deteriorating [57] leading to a re-
duction in the medicinal plant resource base. This may
be exacerbated by commercialization of medicinal plants
(e.g. [58]). There are presently only few attempts at in-
creasing the production of medicinal plants [59]. If over-
exploitation of the natural medicinal plant resource
persists higher prices will lead to lower consumption, un-
less the resource is domesticated [60].
Production systems refer to the general production struc-
ture in a country, including both traded and non-traded
production in both urban and rural sectors; this structure
determines land use patterns. Policies and budgets may
(intentionally or unintentionally) directly influence the type,
size and geographical location of production systems (N2).
For instance, the 1999 Brazilian currency devaluation com-
bined with an international price increase of soybeans and
beef and control of hoof and mouth disease led to large
scale replacement of savannah woodland, known to supply
medicinal plants [61], by soybean and cattle in central-west
Brazil [54]. Production systems are constantly changing, e.
g. in response to subsidy programs or new or collapsing
markets [62]. Changes in production systems in turn,
through both pull and push factors, influence patterns of
migration and rates of urbanization (N6). For instance, the
collapse of the agricultural sector in El Salvador during the
civil war led to large scale internal and international migra-
tion, including rapid growth in the capital city [47]. In the
1960s many Nepalese farmers moved from hill areas to
lowlands in response to overcrowding and stagnant agricul-
tural productivity (push) in the hills, and eradication of
malaria and agricultural land availability (pull) in the low-
lands [63]. While the global population growth rate has
declined since the late 1960s, substantial population
increases are still expected in some regions, e.g. in sub-
Saharan Africa, and are projected to be concentrated in
low-income urban communities [64].
Households’ livelihood strategies, defined as income
generating activities conditioned by assets and mediated
by institutional and social relations [65], result fromproduction related decisions (that, amongst other things,
are based on pre-existing characteristics such as land
and labour availability). Changes in production systems
can directly affect livelihood strategies (N7). For
example, the Chinese government’s conservation and
development policies have lead to a vast sedentarization
movement of Tibetan households and connectedly to
a shift from a livestock rearing based livelihood to an
agricultural-based livelihood [66]. The production sys-
tem structure can also directly influence the type and
level of health threats faced locally (N5), e.g. conversion
of forest to agricultural production in Northern Thailand
led to a decline in malaria threat caused by the Anoph-
eles mosquito, occupying forest habitats [67].
Policies and budgets also influence medicinal plant
demand by defining national health policies and thereby
local access to health care options (N3), e.g. through
public funding of hospitals and clinics [68-70]. Lastly,
policies and budgets directly impact on the types and
levels of disease threats faced locally, regionally, and na-
tionally (N4), e.g. through provision of safe drinking
water and sanitation or maintenance of disaster manage-
ment regimes (e.g. [71,72]).Local level
Medicinal plants are supplied from wild and domesti-
cated vegetation types that can be described by their
size, species composition, and quality. The global num-
ber of medicinal plant species is estimated at almost
53,000 [73], corresponding to 10-18% of the world’s
vascular plant species [74]. Except for the few hundred
species in cultivation [73] these are all wild harvested
and there is thus a close link between renewable natural
resources (forests, meadows, etc.) and human health.
However, it should be noted that domestication takes
place along a gradient of increasing human energy input
per plant and that low energy input supply mechanisms
may be important, e.g. households may access weeds
[75] or maintain supplies in house gardens [76]. As bio-
diversity is degraded [77] the opportunities of medicinal
plant use for health care will change.
Resource management systems, ranging from open
access to complete protection, influence the potential
and actual supply of medicinal plants (L1). In the past
decades, a growing realization of the inability of central
authorities to monitor, let alone manage, distant natural
resources has led to increasing decentralization in devel-
oping countries [78]. In consequence, open access regimes
give way to collective action with higher potentials for
sustainable management and stable supply of products
such as medicinal plants [79,80]. A limitation on man-
agement is lack of basic information on frequency and
growth of most medicinal plant species [81]. But even in
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arise when the supply of highly demanded medicinal
plants is threatened [82,83].
Health care options cover access to public and private
health care choices. Traditionally, public health care
systems in most countries are singular [84], with some
notable exceptions such as in China and India, promot-
ing the use of allopathic medicine with no or little public
support for traditional medicine in terms of research,
medical insurance or other aspects. Increasingly, how-
ever, public health care systems are becoming more
pluralistic, incorporating traditional medicine practices
to supplement allopathic treatment and to more effect-
ively reach the rural population, e.g. in treatment of
HIV/AIDS in Africa (e.g. [85-87]). There are also exam-
ples of allopathic therapists in developed countries using
traditional medicine (e.g. [88,89]). There are very few
studies of how increasing pluralistic public health care
impacts on the user demand for medicinal plants (L2).
Increased budgets for pluralistic public health care in
developed countries would probably increase consump-
tion of medicinal plants, whereas in developing coun-
tries, where public health care systems often have
limited reach, the impact may be less pronounced, in
particular outside urban areas.
Users’ demand for medicinal plants is influenced by
the type and level of health threats that they are facing
(L3) [90]. Type refers to the category of threat (e.g. in-
fectious diseases) and level to the intensity of the threat
(e.g. epidemic). Where a choice between allopathic and
traditional medicine exists, e.g. in developed countries
and among the better-off in urban areas of developing
countries, it appears that allopathic medicines are often
recurred to in case of serious (often infectious) diseases,
whereas traditional medicine is more often used to
counter mild diseases (e.g. [34,91]). For epidemics such
as HIV/AIDS traditional medicine is likely to be used
as a supplement or a last resort only [92]. In a number
of developing countries, low public health budgets and
subsequent lack of access to allopathic medicine lead to
recurrence to traditional medicines when dealing with
epidemics (e.g. [93]), especially in rural areas. Further-
more, increased resistance to allopathic drugs means
that traditional medicines are sought to treat diseases
such as malaria [94]. The higher frequency of serious
diseases and generally higher threat levels expected as
a consequence of climate changes will likely mean
increased consumption of both allopathic and traditional
medicine. It should be noted that different communities
may have different adaptation capacities, e.g. in relation
to climate changes. Such differences in vulnerability are
not well understood [7].
Urbanization is increasing particularly in the tropics
[95]. Migration and urbanization have been shown toaffect the type and level of threats around the world
(L4). For example, urbanization in Africa has lead to a
profound decrease in morbidity and mortality from mal-
aria due to a detrimental effect of city environments on
anopheline species’ diversity, numbers, survival rates and
infection rates [96].
Household level
Medicinal plant consumption is determined by demand
and available stocks (H5, H6). As most medicinal plant
species are harvested in the wild, the extractivism cycle
proposed by Homma [60] provides a useful starting
point for analyzing medicinal plant production over time
at the single species level. Generally, as medicinal plant
demand is probably growing while the resource base is
shrinking, it will be challenging to maintain consump-
tion in the future. While there are good published spe-
cies level treatments of plant uses and location-specific
studies with detailed species level stock and flow infor-
mation, i.e. studies estimating available harvestable
amounts and actual levels of extraction in particular
locations (e.g. [97,98]), there are no studies providing
stock and flow information for a species across its distri-
bution range.
User demand for medicinal plants, expressed by indi-
vidual decisions on preventive and curative treatment
resorts, are influenced by user characteristics (H2). In
developed countries, the use of traditional medicine is
positively correlated with income [36,91,99], it is mainly
used to maintain health [36,100,101] and it is related to
a positive comparison with allopathic therapists in terms
of patient care [92] and effectiveness [91,92,102]. It
appears that traditional medicine expense is an add-
itional cost that does not substitute allopathic medicine
costs [99,103]. The proportion of the population aged
over 60 years in developed countries is predicted to in-
crease from 19% to 32% by 2050 [104] and it appears
reasonable to assume that this will lead to an increased
demand for both allopathic and traditional medicines. In
developing countries, traditional medicine is resorted to
because it is the only option (e.g. [69,105]) or the
preferred option, e.g. due to better patient care
(e.g. [106,107]). It is increasingly documented that people
in developing countries resort to parallel treatments
with traditional and allopathic medicine and that the
choice is pragmatic rather than cultural (e.g. [108-111]).
The increased availability of allopathic medicine in devel-
oping countries will therefore likely decrease the use of
traditional medicine, but not displace it.
Livelihood strategies of households can be affected
by patterns of migrationb and urbanization (H4). For
example, migration is often a way to increase or diversify
income and/or to ensure access to assets for rural popu-
lations [112]. In turn, livelihood strategies influence
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istics (H3), e.g. through the physical and human assets
available for investing in disease preventive measures
such as boiling drinking water [72] and financial assets
available for meeting treatment costs.
User demand for medicinal plants is thus shaped by
user characteristics (H2), and determined by available
health care options (L3) and perceptions of threats (L4),
as well as by medicinal plant supply (H1). Again, note
the dual nature of the directional causality, e.g. user pre-
ferences can both promote and discourage the consump-
tion of medicinal plants.Discussion
Medicinal plants appear to particularly provide poorer
people in developing countries with affordable health
care options, and well-off people in developed countries
with health maintenance options. Current general devel-
opment trends in developing (population increase, poor
coverage of western health care, accessibility of trad-
itional medicines) and developed (aging populations)
countries indicate that medicinal plant consumption is
not likely to decrease in the short to medium term -
consumer, producer and society-wide medicinal plant
benefits will persist. Therefore, and regardless of the
constraints to the development of a sound evidence base
on safety and efficacy for herbal medicines [113] and
related products, we should improve our understanding
of what drives medicinal plant consumption. Informa-
tion on these drivers will constitute important building
blocks in designing pluralistic health policies and
improved natural resources management interventions
to the benefits of hunter-gatherers, farmers and pastoral-
ists, urban and peri-urban people, and entrepreneurs
across the globe.
The presented unified conceptual framework offers a
first step towards establishing a comprehensive approach
to understanding the dynamics of medicinal plant con-
sumption. At present the literature is dominated by
studies that are disciplinary or sectoral focused; while
many of these are high quality and informative in them-
selves, the lack of a general conceptual framework makes
it difficult to pinpoint what spatial levels and causal fac-
tors need attention. The framework presented here fills
in this knowledge gap by providing a structured ap-
proach to systematically investigate changes in medicinal
plant consumption based on changes in key factors. For
instance, it emphasizes the importance of assessing the
impact caused by changes in land use patterns on medi-
cinal plant consumption. An alternative approach to the
presented framework would be to develop a mathemat-
ical model that would allow more detailed analysis, e.g.
of feed-back loops. However, given existing data gapsand the lack of knowledge on key factors, such models
would require a heroic number of assumptions and
would be less transparent than the proposed framework.
At present, a systematic endeavour to fill the vast
knowledge gaps in our understanding of medicinal plant
consumption dynamics is needed to inform future health
and natural resource management policies. Apart from
increasing our conceptual understanding of medicinal
plant consumption dynamics, the proposed framework
can serve to guide research towards systematically
pursuing this objective. Standardized international or
national surveys do not presently include the concept of
medicinal plant reliance, and in many cases only limited
information on the main causal factors and linkages
to medicinal plant consumption will be available at
the country level, thus making it difficult to measure
the central variables (assessing the strength of factors,
linkages and their impacts on future consumption).
Therefore, a next step in operationalising the framework
could be to develop an analytical framework enabling
country-level comparative studies of changes in medi-
cinal plant consumption, e.g. through the identification
of a set of generic indicators and a research protocol.Limitations of the framework
We acknowledge that creating a single unified frame-
work aimed at uncovering the determinants affecting
medicinal plant consumption at the international,
national, local and household levels is a bold venture;
however, this comprehensive approach is necessary to
illustrate and understand the multiple and complex fac-
tors influencing medicinal plant consumption. A similar
approach has been successfully used to create a frame-
work that formed the basis for analytical dissection and
understanding of the complexities of tropical deforest-
ation [114].
It should be noted that the presented conceptual
framework does not portray the full complexity of lin-
kages, nor does it depict temporal (bi-directional) lin-
kages, e.g. resource management systems will over time
impact on medicinal plant resource productivity. It
should also be noted that the factors and linkages consti-
tute a “gross list” of what is potentially important – not
all factors and linkages will be important in any particu-
lar geographical location and their relative importance
may vary across time.
The four medicinal plant user groups depicted in
the first part of the paper are based on generalizations
(e.g. hunter-gatherer communities are generally seen as
remote and poor while farmers are generally seen as
wealthier and with access to better infrastructure). While
acknowledging the risk of excluding certain communities
which do not conform to the general patterns observed
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structure when reflecting on which types of people and
communities are reliant on medicinal plants.
Conclusions
Current evidence indicates that a huge number of people
rely on medicinal plant products to maintain their health
or treat illnesses, and that this number is unlikely to
decrease in the foreseeable future. The paper inductively
synthesises available scattered knowledge on medicinal
plant production, trade and consumption to propose a
conceptual framework identifying the factors, and their
interconnectedness, determining medicinal plant con-
sumption. The framework is based on a typology of
main medicinal plant user groups (hunter-gatherers,
farmers and pastoralists, urban and peri-urban residents,
and entrepreneurs) and three basic kinds of benefits
(producer, consumer, and society-wide). Factors and lin-
kages in the proposed framework range from inter-
national to household levels and, though necessarily
broad, it can thus facilitate the construction of inter-
nationally comparable knowledge. The proof of success,
however, is whether the proposed framework will stimu-
late research that is empirically and theoretically richer
than in the past and whether the resultant outcomes will
more effectively contribute to improved human health
and better medicinal plant resource management.
End notes
a Although it has been argued that the term traditional
medicine should only be used for medicine which has
been commonly practiced for more than a generation
[115,116], we adopt a WHO working definition of trad-
itional medicine: “Health practices, approaches, know-
ledge and beliefs incorporating plant, animal and mineral
based medicines, spiritual therapies, manual techniques
and exercises, applied singularly or in combination to
treat, diagnose and prevent illnesses or maintain well-
being” [117]. A crude distinction can be made between
‘imported’ and ‘native’ traditional medicines. For in-
stance, some traditional medicine practices have been
imported to Europe with migrants (e.g. [118]) and could
be termed ‘imported’; however, the distinction becomes
blurred over time. Far from all components of traditional
medicine include use of medicinal plants. Traditional
and allopathic medicine systems may occur side by side
in the same location. Allopathic medicine is the term
used for industrially produced pure, standardized com-
pounds, which are tested for efficacy and side-effects.
b In analyzing migration, human patterns of spatial
mobility, it is useful to distinguish international and do-
mestic migration, and permanent and short-term migra-
tion. The latter is also known as circulation. There is
no single generally accepted model of migration [64]and projections are difficult. In the framework, the
“Migration and urbanization” factor includes all kinds of
migration (the relevant kind of migration will vary with
the case being studied).
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